SANES

10.14

-0.18%↓

BBVA

18.835

+0.16%↑

BNP

87.33

-2.21%↓

CABK

11.005

+0.69%↑

INGA

25.17

-0.61%↓

SANES

10.14

-0.18%↓

BBVA

18.835

+0.16%↑

BNP

87.33

-2.21%↓

CABK

11.005

+0.69%↑

INGA

25.17

-0.61%↓

SANES

10.14

-0.18%↓

BBVA

18.835

+0.16%↑

BNP

87.33

-2.21%↓

CABK

11.005

+0.69%↑

INGA

25.17

-0.61%↓

SANES

10.14

-0.18%↓

BBVA

18.835

+0.16%↑

BNP

87.33

-2.21%↓

CABK

11.005

+0.69%↑

INGA

25.17

-0.61%↓

SANES

10.14

-0.18%↓

BBVA

18.835

+0.16%↑

BNP

87.33

-2.21%↓

CABK

11.005

+0.69%↑

INGA

25.17

-0.61%↓

Home・Elenco Azioni・Sartorius Stedim Biotech.

Sartorius Stedim Biotech.

Chiusa

SettoreFinanza

159 1.66

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

155.8

Massimo

162.5

Metriche Chiave
By Trading Economics
Entrata	41M 88M
Vendite	-11M 762M
P/E Media del settore	59.529 57.736
EPS	1.17
Margine di Profitto	11.569
Dipendenti	10,456
EBITDA	26M 225M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+49.45% upside

Dividendi
By Dow Jones
Utili prossimi	23 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-2.2B 16B
Apertura precedente	157.34
Chiusura precedente	159

Notizie sul Sentiment di mercato

By Acuity

71%

29%

376 / 438 Classifica in Finance

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

202.7 / 211.7 Supporto e resistenza

Sartorius Stedim Biotech. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 mag 2026, 23:10 UTC

Azioni calde

Stocks to Watch: Agilysys, XP

18 mag 2026, 18:44 UTC

I principali Market Mover

Claritev Shares Recover After Comments About DOJ

18 mag 2026, 23:55 UTC

Utili

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 mag 2026, 23:47 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

18 mag 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 mag 2026, 23:37 UTC

Discorsi di Mercato

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 mag 2026, 22:31 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 mag 2026, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 mag 2026, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 mag 2026, 22:25 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 mag 2026, 22:24 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

18 mag 2026, 20:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

18 mag 2026, 20:25 UTC

Utili

Correct: XP 1Q Total Client Assets BRL1.53T

18 mag 2026, 20:23 UTC

Utili

XP 1Q Total Client Assets BRL1.53B

18 mag 2026, 20:19 UTC

Utili

XP 1Q Adj EPS BRL2.49 >XP

18 mag 2026, 20:19 UTC

Utili

XP 1Q Rev BRL4.73B >XP

18 mag 2026, 19:10 UTC

Discorsi di Mercato

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 mag 2026, 19:00 UTC

Utili

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 mag 2026, 18:52 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 mag 2026, 18:17 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 mag 2026, 17:22 UTC

Discorsi di Mercato

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 mag 2026, 16:57 UTC

Acquisizioni, Fusioni, Takeovers

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 mag 2026, 16:57 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

18 mag 2026, 16:57 UTC

Discorsi di Mercato

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 mag 2026, 16:54 UTC

Acquisizioni, Fusioni, Takeovers

Vinci Doesn't Set Out Financial Details of Deal

18 mag 2026, 16:50 UTC

Acquisizioni, Fusioni, Takeovers

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 mag 2026, 16:49 UTC

Acquisizioni, Fusioni, Takeovers

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 mag 2026, 16:49 UTC

Acquisizioni, Fusioni, Takeovers

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 mag 2026, 16:48 UTC

Acquisizioni, Fusioni, Takeovers

Vinci Buys Canada's Modern Group of Companies

Confronto tra pari

Modifica del prezzo

Sartorius Stedim Biotech. Previsione

Obiettivo di Prezzo

By TipRanks

49.45% in crescita

Previsioni per 12 mesi

Media 233 EUR 49.45%

Alto 262 EUR

Basso 210 EUR

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

202.7 / 211.7Supporto e resistenza

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

376 / 438 Classifica in Finanza

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.